<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485092</url>
  </required_header>
  <id_info>
    <org_study_id>GN15CA580</org_study_id>
    <nct_id>NCT03485092</nct_id>
  </id_info>
  <brief_title>Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects</brief_title>
  <acronym>SUGAR-DM-HF</acronym>
  <official_title>Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus (or Pre-diabetes) and Heart Failure (SUGAR-DM-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Greater Glasgow and Clyde</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesise that empagliflozin 10mg daily will have haemodynamic, cardiac,&#xD;
      and renal benefits compared to placebo over 36 weeks in heart failure patients with type 2&#xD;
      diabetes (or pre-diabetes), leading to measurable improvements in clinical measures of&#xD;
      cardiac structure and function (LVESVI, and LV strain) as well as renal blood flow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The results of the EMPA-REG OUTCOME trial on CVD outcomes and heart failure hospitalisation&#xD;
      suggests that empagliflozin works quickly to lessen CVD mortality and reduce heart failure&#xD;
      hospitalisations in patients with diabetes and existing cardiovascular disease. The lack of&#xD;
      effect on non-fatal MI and stroke would suggest limited impact on atherothrombotic&#xD;
      mechanisms. It is important to understand the mechanisms by which empagliflozin is acting in&#xD;
      more detail, in order that the drug can be more widely targeted at patient groups that might&#xD;
      benefit most; particularly patients with heart failure and diabetes (or pre-diabetes) (as&#xD;
      discussed in the rationale).&#xD;
&#xD;
      The investigators have hypothesised, in a detailed published review, that the benefit derives&#xD;
      from the specific effects of sodium-glucose linked transporter-2 (SGLT2) inhibition on renal&#xD;
      sodium and glucose handling, leading to both diuresis and improvements in diabetes-related&#xD;
      maladaptive renal arteriolar responses. These haemodynamic and renal effects are likely to be&#xD;
      beneficial in patients with clinical or subclinical cardiac dysfunction. The net result of&#xD;
      these processes is an improvement in cardiac systolic and diastolic function and, thereby, a&#xD;
      lower risk of heart failure hospitalisation (HFH) and sudden cardiac death.&#xD;
&#xD;
      The investigators have therefore designed the present trial to perform a comprehensive&#xD;
      clinical trial to interrogate in detail the effects of empagliflozin on specific pathways&#xD;
      (inclusive of cardiac and renal effects) in patients with type 2 diabetes (or pre-diabetes)&#xD;
      and heart failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Actual">March 28, 2020</completion_date>
  <primary_completion_date type="Actual">March 28, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, placebo controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>placebo controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular End Systolic Volume Index (LVESVI)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Cardiac structure measured by left ventricular end-systolic volume index measured by cardiac magnetic resonance imaging as mL/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>left ventricular global longitudinal strain (GLS)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Cardiac structure measured by left ventricular global longitudinal strain measured by cardiac magnetic resonance imaging GLS%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end diastolic volume index (LVEDVI)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Left ventricular end diastolic volume index (LVEDVI) measured by Cardiac MR in ml/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Left ventricular ejection fraction (LVEF) measured by Cardiac MR in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass index (LVMI)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Left ventricular mass index (LVMI) measured by cardiac MR in grams/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular global function index (LVGFI)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Left ventricular global function index (LVGFI) measured by cardiac MR in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrial volume index (LAVI)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Left atrial volume index (LAVI) measured by cardiac MR in ml/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular perfusion</measure>
    <time_frame>36 weeks</time_frame>
    <description>Microvascular perfusion measured by Gadolinium enhanced Cardiac magnetic resonance imaging measured as ml/min/g</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracellular volume fraction</measure>
    <time_frame>36 weeks</time_frame>
    <description>Extracellular volume fraction measured by Gadolinium enhanced Cardiac magnetic resonance imaging measured as %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire Total Symptom score (TSS) measured by mean overall difference and responder analysis (higher score = better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk distance (Exercise Capacity)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Exercise capacity measured by six minute walk test measured in m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary congestion</measure>
    <time_frame>36 weeks</time_frame>
    <description>Pulmonary congestion as B-lines measured using lung ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker profile -glycated haemaglobin (HbA1c)</measure>
    <time_frame>36 weeks</time_frame>
    <description>biomarker profile of HbA1c (mmol/mol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker profile - creatine</measure>
    <time_frame>36 weeks</time_frame>
    <description>biomarker profile of creatine (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker profile - estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>36 weeks</time_frame>
    <description>biomarker profile of eGFR (ml/min/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker profile - liver function tests (LFTs)</measure>
    <time_frame>36 weeks</time_frame>
    <description>biomarker profile of LFTs (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker profile - uric acid</measure>
    <time_frame>36 weeks</time_frame>
    <description>biomarker profile of uric acid (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensification of diuretic therapy</measure>
    <time_frame>36 weeks</time_frame>
    <description>Intensification of diuretic therapy through addition and/or increase dose of diuretic medication</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Left ventricular global longitudinal strain (GLS)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Left ventricular global longitudinal strain (GLS) measured by CMR tagging measured in percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>Left ventricular global circumferential strain (GCS)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Left ventricular global circumferential strain (GCS) measured in CMR featured-tracking and tagging in percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>Left ventricular global radial strain (GRS)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Left ventricular global radial strain (GRS)measured in CMR featured-tracking and tagging in percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>total renal blood flow measured by magnetic resonance imaging</measure>
    <time_frame>36 weeks</time_frame>
    <description>total renal blood flow measure using cardiac magnetic resonance imaging measured as ml/min/100g</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal fibrosis</measure>
    <time_frame>36 weeks</time_frame>
    <description>Renal fibrosis measured by T1 mapping in MRI in miiliseconds</description>
  </other_outcome>
  <other_outcome>
    <measure>Bioelectrical impedance analysis</measure>
    <time_frame>36 weeks</time_frame>
    <description>Bioelectrical impedance analysis in percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical composite outcome of death, hospitalisation with worsening heart failure, ED visit for worsening heart failure, outpatient worsening of heart failure accompanied by increase in HF therapy</measure>
    <time_frame>36 weeks</time_frame>
    <description>Clinical composite outcome of death, hospitalisation with worsening heart failure, ED visit for worsening heart failure, outpatient worsening of heart failure accompanied by increase in HF therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical composite analysed using Win-ratio approach</measure>
    <time_frame>36 weeks</time_frame>
    <description>Clinical composite (analysed using Win-ratio approach) outcome of death, hospitalisation with worsening heart failure, ED visit for worsening heart failure, outpatient worsening of heart failure accompanied by increase in HF therapy, KCCQ-TSS &gt;5-point decrease, or no decrease, &gt;30% in NT-proBNP from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Left ventricular diastolic function</measure>
    <time_frame>36 weeks</time_frame>
    <description>Left ventricular diastolic function measured by echocardiogram</description>
  </other_outcome>
  <other_outcome>
    <measure>DNA and epigenetics</measure>
    <time_frame>36 weeks</time_frame>
    <description>DNA and epigenetic analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Heart Failure</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empagliflozin 10mg tablets for oral self-administration once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablets for oral self-administration once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>Empagliflozin 10mg tablets for oral self administration once a day</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo tablets for oral self administration once a day</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Male or female, aged ≥18 years age&#xD;
&#xD;
          -  Type 2 DM (diet-controlled or on stable treatment) or prediabetes&#xD;
&#xD;
               -  Stable treatment defined as no change in oral therapy agents or doses for&#xD;
                  diabetes mellitus and (where applicable) &lt;10% change in average total daily&#xD;
                  insulin dose over last 6 weeks&#xD;
&#xD;
               -  HbA1c ≤97 mmol/mol (11%) (routine available data from medical records, recorded&#xD;
                  in the last year)&#xD;
&#xD;
               -  Prediabetes defined as HbA1c 39-47 mmol/mol (5.7-6.4%) at the time of screening&#xD;
                  (specifically for the prediabetes group, HbA1c will be repeated at the time of&#xD;
                  screening if there are no recent results within the last 3 months, in order to&#xD;
                  confirm the diagnosis of prediabetes)&#xD;
&#xD;
          -  Heart failure (as defined by the presence of typical signs and symptoms of heart&#xD;
             failure with documented reduced ejection fraction (ref SIGN and ESC guidelines))&#xD;
&#xD;
               -  NYHA class II-IV&#xD;
&#xD;
               -  LVEF ≤40%&#xD;
&#xD;
               -  On stable doses of ACEI, ARB or ARNI for 4 weeks prior to randomisation unless&#xD;
                  contraindicated or not tolerated. They should also be taking a beta-blocker at a&#xD;
                  stable dose for 4 weeks unless contraindicated or not tolerated&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must be currently adhering to, or be willing&#xD;
             to use, highly effective birth control methods for study treatment duration including:&#xD;
&#xD;
               -  Combined hormonal contraception (oestrogen and progestogen containing medication)&#xD;
                  either orally, intravaginally, or transdermally&#xD;
&#xD;
               -  Progesterone only hormonal contraception either orally, injected, or implanted&#xD;
&#xD;
               -  Intrauterine device (IUD)&#xD;
&#xD;
               -  Intrauterine hormone release system (IUS)&#xD;
&#xD;
               -  Bilateral fallopian tube occlusion&#xD;
&#xD;
               -  Vasectomised partner&#xD;
&#xD;
               -  Complete sexual abstinence where this is their preferred and usual lifestyle&#xD;
&#xD;
        WOCBP comprises women who have experienced menarche and who have not undergone successful&#xD;
        surgical sterilisation (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy)&#xD;
        or who are not post-menopausal. Post-menopausal is defined as:&#xD;
&#xD;
        o Women who have had amenorrhea for ≥12 consecutive months (without another medical cause)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 DM&#xD;
&#xD;
          -  History of hospital admission with a diagnosis of diabetic ketoacidosis (DKA)&#xD;
&#xD;
          -  Insulin use within 1 year of diagnosis of diabetes&#xD;
&#xD;
          -  History of acute or chronic pancreatitis&#xD;
&#xD;
          -  eGFR &lt;30 ml/min/1.73m2 (derived using CKD EPI)&#xD;
&#xD;
          -  Persistent/permanent atrial fibrillation/flutter (conditions which significantly&#xD;
             impede MRI image interpretability)&#xD;
&#xD;
          -  Acute coronary syndrome, stroke or surgery within 1 month (small type 2 MI in the&#xD;
             context of acute HF does not apply)&#xD;
&#xD;
          -  BMI &gt;52 kg/m2&#xD;
&#xD;
          -  Liver disease, defined by serum levels of alanine aminotransferase, aspartate&#xD;
             aminotransferase, or alkaline phosphatase above 3 x upper limit of normal (ULN) during&#xD;
             screening&#xD;
&#xD;
          -  Bariatric surgery within the past two years and other gastrointestinal surgeries that&#xD;
             induce chronic malabsorption&#xD;
&#xD;
          -  Any condition outside the cardiovascular and renal disease area, such as but not&#xD;
             limited to malignancy, with a life expectancy of less than 2 years based on&#xD;
             investigator's clinical judgement&#xD;
&#xD;
          -  Active malignancy requiring treatment at the time of visit 1 (with the exception of&#xD;
             successfully treated basal cell or treated squamous cell carcinoma, adjuvant hormonal&#xD;
             therapy for breast cancer and hormone therapy for prostate cancer)&#xD;
&#xD;
          -  Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells (e.g.&#xD;
             malaria, babesiosis, haemolytic anaemia)&#xD;
&#xD;
          -  Treatment with systemic steroids at time of informed consent or change in dosage of&#xD;
             thyroid hormones within 6 weeks prior to informed consent&#xD;
&#xD;
          -  Any uncontrolled endocrine disorder except Type 2 DM&#xD;
&#xD;
          -  Alcohol or drug abuse within 3 months of informed consent that would interfere with&#xD;
             trial participation or any ongoing condition leading to decreased compliance with&#xD;
             study procedures or study drug intake&#xD;
&#xD;
          -  Known hypersensitivity to the empagliflozin or excipients&#xD;
&#xD;
          -  Known hypersensitivity to gadolinium&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  SGLT2 inhibitor use (current or previous)&#xD;
&#xD;
          -  Devices or any other contraindication to MRI scans&#xD;
&#xD;
          -  Currently pregnant, planning pregnancy, or currently breastfeeding&#xD;
&#xD;
          -  History of previous lower limb amputation&#xD;
&#xD;
          -  Current participation in another interventional medical study or within the last 90&#xD;
             days&#xD;
&#xD;
          -  Anyone who, in the investigators' opinion, is not suitable to participate in the trial&#xD;
             for other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naveed Sattar, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Glasgow University and NHS GGC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.</citation>
    <PMID>26378978</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>empagliflozin</keyword>
  <keyword>Randomised, placebo controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

